
|Articles|February 7, 2020
Glaucoma 360 shines spotlight on innovation
Author(s)Sheryl Stevenson, Alex Delaney-Gesing
Advertisement
Glaucoma 360 co-founders and co-chairs Adrienne Graves, PhD, and Andrew Iwach, MD, sit down with Ophthalmology Times' Sheryl Stevenson to discuss a few of the highlights for this year’s meeting in San Francisco.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial
2
Remigromig noninferior to ranibizumab in phase 2b/3 BRUNELLO DME trial
3
Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP
4
Retina Society 2026: Ocular syphilis, HIV co-infection, and RPR titers
5










